- Home
- GIGM vs TLPH Comparison
GIGM vs TLPH Comparison
Compare GIGM & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- TLPH
- Stock Information
- Founded
- GIGM 1998
- TLPH 2005
- Country
- GIGM Taiwan
- TLPH United States
- Employees
- GIGM N/A
- TLPH N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- TLPH Health Care
- Exchange
- GIGM Nasdaq
- TLPH Nasdaq
- Market Cap
- GIGM 17.0M
- TLPH 11.1M
- IPO Year
- GIGM 2000
- TLPH 2011
- Fundamental
- Price
- GIGM $1.83
- TLPH $0.98
- Analyst Decision
- GIGM
- TLPH Strong Buy
- Analyst Count
- GIGM 0
- TLPH 1
- Target Price
- GIGM N/A
- TLPH $6.00
- AVG Volume (30 Days)
- GIGM 23.8K
- TLPH 7.3M
- Earning Date
- GIGM 10-29-2025
- TLPH 11-12-2025
- Dividend Yield
- GIGM N/A
- TLPH N/A
- EPS Growth
- GIGM N/A
- TLPH N/A
- EPS
- GIGM N/A
- TLPH N/A
- Revenue
- GIGM $3,250,000.00
- TLPH $27,000.00
- Revenue This Year
- GIGM N/A
- TLPH N/A
- Revenue Next Year
- GIGM N/A
- TLPH $14,533.26
- P/E Ratio
- GIGM N/A
- TLPH N/A
- Revenue Growth
- GIGM N/A
- TLPH N/A
- 52 Week Low
- GIGM $1.30
- TLPH $0.38
- 52 Week High
- GIGM $1.89
- TLPH $1.20
- Technical
- Relative Strength Index (RSI)
- GIGM 69.35
- TLPH 58.69
- Support Level
- GIGM $1.61
- TLPH N/A
- Resistance Level
- GIGM $1.89
- TLPH $1.20
- Average True Range (ATR)
- GIGM 0.09
- TLPH 0.12
- MACD
- GIGM 0.03
- TLPH 0.01
- Stochastic Oscillator
- GIGM 85.71
- TLPH 81.67
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.